Karyopharm Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
KPTI$0.02-56.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net loss | $(37,362) | $(34,126) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,970 | 5,389 |
| Depreciation and amortization | 85 | 290 |
| Amortization of debt issuance costs | 208 | 201 |
| Net amortization of premiums and discounts on investments | (911) | (1,126) |
| Other | — | 4 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (4,120) | 11,886 |
| Inventory | 274 | 397 |
| Prepaid expenses and other assets | (3,665) | 1,537 |
| Operating lease right-of-use assets | 541 | 462 |
| Accounts payable | 1,905 | 6,272 |
| Accrued expenses and other liabilities | (4,862) | (9,414) |
| Operating lease liabilities | (788) | (682) |
| Net cash used in operating activities | (43,725) | (18,910) |
| Investing activities | ||
| Proceeds from maturities of investments | 53,743 | 27,944 |
| Purchases of investments | (31,608) | (60,332) |
| Purchases of property and equipment | (195) | — |
| Net cash provided by (used in) investing activities | 21,940 | (32,388) |
| Effect of exchange rate on cash, cash equivalents and restricted cash | (16) | (45) |
| Net decrease in cash, cash equivalents and restricted cash | (21,801) | (51,343) |
| Cash, cash equivalents and restricted cash at beginning of period | 53,192 | 136,885 |
| Cash, cash equivalents and restricted cash at end of period | $31,391 | $85,542 |
| Reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $30,628 | $84,062 |
| Short-term restricted cash | 459 | 846 |
| Long-term restricted cash | 304 | 634 |
| Total cash, cash equivalents and restricted cash | $31,391 | $85,542 |
| Supplemental disclosures: | ||
| Cash paid for amounts included in the measurement of operating lease liabilities | $948 | $923 |
| Cash paid for interest on deferred royalty obligation | $4,103 | $4,076 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.